Literature DB >> 5487064

Phase specificity of 5-azacytidine against mammalian cells in tissue culture.

L H Li, E J Olin, T J Fraser, B K Bhuyan.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1970        PMID: 5487064

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


× No keyword cloud information.
  15 in total

1.  Inhibition of cephalic neural tube closure by 5-azacytidine in neurulating rat embryos in vitro.

Authors:  M Matsuda; M Yasutomi
Journal:  Anat Embryol (Berl)       Date:  1992

2.  Azacitidine Mitigates Graft-versus-Host Disease via Differential Effects on the Proliferation of T Effectors and Natural Regulatory T Cells In Vivo.

Authors:  Matthew L Cooper; Jaebok Choi; Darja Karpova; Kiran Vij; Julie Ritchey; Mark A Schroeder; John F DiPersio
Journal:  J Immunol       Date:  2017-03-22       Impact factor: 5.422

Review 3.  Novel Therapies for Acute Myeloid Leukemia: Are We Finally Breaking the Deadlock?

Authors:  Maximilian Stahl; Benjamin Y Lu; Tae Kon Kim; Amer M Zeidan
Journal:  Target Oncol       Date:  2017-08       Impact factor: 4.493

4.  Localization of the labelled 5-azacytidine in cultured mouse embryonic cells.

Authors:  M Seifertová; J Veselý; A Cihák
Journal:  Experientia       Date:  1974-12-15

5.  Cell cycle effects and cellular pharmacology of 5-aza-2'-deoxycytidine.

Authors:  R L Momparler; J Samson; L F Momparler; G E Rivard
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

Review 6.  Antineoplastic drugs: clinical pharmacology and therapeutic use.

Authors:  R A Bender; L A Zwelling; J H Doroshow; G Y Locker; K R Hande; D S Murinson; M Cohen; C E Myers; B A Chabner
Journal:  Drugs       Date:  1978-07       Impact factor: 9.546

7.  Sequence-dependent toxicity and small bowel mucosal injury in neonatal mice treated with low doses of 5-azacytidine and X-irradiation at the late organogenesis stage.

Authors:  W Schmahl
Journal:  Radiat Environ Biophys       Date:  1983       Impact factor: 1.925

Review 8.  Treatment options in advanced myelodysplastic syndrome, with emphasis on epigenetic therapy.

Authors:  Yasuhiro Oki; Jean-Pierre J Issa
Journal:  Int J Hematol       Date:  2007-11       Impact factor: 2.490

9.  Pharmacokinetics and Pharmacodynamics with Extended Dosing of CC-486 in Patients with Hematologic Malignancies.

Authors:  Eric Laille; Tao Shi; Guillermo Garcia-Manero; Christopher R Cogle; Steven D Gore; Joel Hetzer; Keshava Kumar; Barry Skikne; Kyle J MacBeth
Journal:  PLoS One       Date:  2015-08-21       Impact factor: 3.240

10.  Inhibitory effects of epigenetic modulators and differentiation inducers on human medulloblastoma cell lines.

Authors:  Ina Patties; Rolf-Dieter Kortmann; Annegret Glasow
Journal:  J Exp Clin Cancer Res       Date:  2013-05-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.